The Polish version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) - Four-stage translation and validation

Endokrynologia Polska

Volumn 59, Issue 5, 2008, Pages 374-384

  Karbownik Lewińska, Małgorzata ^a,b   Lewiński, Andrzej ^a,b   McKenna, Stephen ^c,d   Kokoszko, Agnieszka ^a,b   Mucha, Sławomir ^a   Komorowski, Jan ^a   Krzyzanowska Świniarska, Barbara ^e   Gryczyńska, Maria ^f   Sowiński, Jerzy ^f   Junik, Roman ^g,h   Meads, David ^d   Kołtowska Häggström, Maria ^i,j  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^d GALEN RESEARCH   (United Kingdom)

^e POMERANIAN MEDICAL UNIVERSITY   (Poland)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^h NICOLAUS COPERNICUS UNIVERSITY   (Poland)

ⁱ PFIZER INC   (United States)

^j UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

GH deficiency in adults; Polish version; QoL AGHDA; Quality of life; Validation

Indexed keywords

ARTICLE; CONSTRUCT VALIDITY; GROWTH HORMONE DEFICIENCY; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY;

ADULT; FEMALE; GREAT BRITAIN; HUMAN GROWTH HORMONE; HUMANS; LANGUAGE; MALE; MIDDLE AGED; POLAND; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; TRANSLATING;

EID: 57649220612     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Acquadro C, Conway K, Giroudet C et al. Linguistic validation manual for patient-reported outcomes (PRO) instruments. Mapi Research Institute, Lyon 2004.
2. Wild D, Grove A, Martin M et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report for the ISPOR task force for translation and cultural adaptation. Value in Health 2005; 8: 94-104.
3. Swaine-Verdier A, Deward LC, Hagell P et al. Adapting quality of life instruments. Value in Health 2004, 7 (Suppl. 1): S27-S30.
4. Abs R, Feldt-Rasmussen U (eds). Growth Hormone Deficiency in Adults: 10 Years of KIMS. Oxford PharmaGenesis™, Oxford 2004.
5. Kołtowska-H⊣ggström M, Hennessy S, Mattsson AF et al. Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency. Horm Res 2005; 64: 46-54.
6. Kołtowska-Häggström M, Mattsson AF, Monson JP et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur J Endocrinol 2006; 155: 109-119.
7. Kołtowska-Häggström M, Kind P, Monson JP et al. Growth hormone (GH) replacement in hypopituitary adults with GH deficiency evaluated by a utility-weighted quality of life index: a precursor to cost-utility analysis. Clin Endocrinol (Oxf) 2008; 68: 122-129.
8. McKenna SP, Doward LC, Alonso J et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999; 8: 373-383.
9. Hunt SM, McKenna SP. The QLDS: A scale for the measurement of quality of life in depression. Health Policy 1992; 22: 307-319.
10. Holmes SJ, McKenna SP, Doward LD et al. Development of a questionnaire to assess the quality of life of adults with GHD. Endocrinol Metab 1995; 2: 63-69.
11. Leplege A, Ecosse E. Pilot study and preliminary validation of the French version of a disease-specific measure for assessing quality of life of adults with growth hormone deficiency. Ann Endocrinol 2003; 64: 191-197.
12. Suzukamo Y, Noguchi H, Takahashi N et al. Validation of the Japanese version of the Quality of Life-Assessment of Growth Hormone deficiency in Adults (QoL-AGHDA). Growth Horm & IGF Res 2006; 16: 340-347.
13. Hunt SM, McKenna SP, McEwen J et al. The Nottingham Health Profile: subjective health status and medical consultation. Soc Sci Med 1981; 15A: 221-229.
14. Saller B, Mattsson AF, Kann PH et al. Healthcare utilization, quality of life and patient-reported outcomes during two years of growth hormone (GH) replacement therapy in GH-deficient adults - comparison between Sweden, The Netherlands and Germany. For J Endocrinol 2006; 154: 843-850.
15. Gutiérrez LP, Kołtowska-Häggström M, Jonsson PJ et al. Registries as Tool in Evidence Based Medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf 2008; 17: 90-102.
16. Hunt SM, Alonso J, Bucquet D et al. Cross cultural adaptation of health measures. Health Policy 1991; 19: 33-44.
17. Weiner EA, Stewart BJ. Assessing individuals. Little Brown, Boston 1984.
18. Streiner DL, Norman GR. Health measurement scales: A practical guide to their development and use. Oxford University Press, Oxford 1989.